NSGl 533/l NSG533l Examl 3l –l Advancedl
Pharmacologyl Guide|l Wilkesl (Latestl
2026/l 2027l Update)l 100%l Verifiedl
Questionsl &l Answersl |l Gradel A
Q:l Vaccinationsl COPD
Answer:
Influenzal vaccine
Pneumococcall vaccine
PCV20l (pneumococcall conjugatel vaccine)l OR
PCV15l followedl byl PPSV23
COVID-19l Vaccine
Pertussisl (Tdap)
Shinglesl (herpesl zoster)
RSV
Thesel reducel riskl ofl respiratoryl infectionsl andl COPDl exacerbations.
Q:l Differencesl inl Pathophysiologyl Betweenl COPDl andl Asthmal andl Theirl Impactl onl
Treatment
Answer:
Pathophysiologyl ofl Asthma
Asthmal isl al chronicl inflammatoryl airwayl diseasel characterizedl by:
Airwayl inflammation
Bronchiall hyperresponsiveness
Reversiblel airflowl obstruction
Thel airwayl narrowingl isl primarilyl duel tol inflammation,l bronchospasm,l andl mucusl
production.
Thel airflowl limitationl inl asthmal isl typicallyl reversiblel withl bronchodilators.
Therapeuticl Approach
Becausel inflammationl isl thel mainl driver,l treatmentl focusesl onl anti-inflammatoryl therapy.
Inhaledl corticosteroidsl (ICS)l arel thel foundationl ofl asthmal treatment.
,Bronchodilatorsl (SABAl orl LABA)l arel usedl tol relievel bronchospasml andl improvel
airflow.
Pathophysiologyl ofl COPD
COPDl isl characterizedl byl chronicl airflowl limitationl thatl isl notl fullyl reversible.
Thel diseasel resultsl from:
Chronicl airwayl inflammation
Structurall airwayl damage
Alveolarl destructionl (emphysema)
Excessl mucusl productionl (chronicl bronchitis)
Thesel changesl cause:
Narrowedl airways
Lossl ofl elasticl recoil
Persistentl airflowl obstruction
Spirometryl isl requiredl forl diagnosis.l COPDl isl confirmedl whenl post-bronchodilatorl
FEV₁/FVCl <l 0.70,l indicatingl persistentl airflowl limitation
Q:l Therapeuticl differencesl inl Asthmal andl COPD
Answer:
Asthma
Focusl onl anti-inflammatoryl therapy
ICSl arel first-linel controllerl medications
COPD
Focusl onl bronchodilationl andl symptoml control
Bronchodilatorsl (LABAl andl LAMA)l arel thel foundationl ofl COPDl therapy
ICSl arel usedl onlyl inl certainl patients,l suchl asl thosel withl frequentl exacerbations
Q:l Majorl Riskl Factorsl COPD
Answer:
1-l Smoking
2-l Age
3-l Male
4-l Impairedl lungl growth
5-l Occupation
6-l Alpha1-l antitrypsinl deficiency
Whyl Providersl Shouldl Encouragel Riskl Factorl Reduction
Reducingl riskl factorsl isl essentiall becausel itl can:
,Slowl diseasel progression
Reducel frequencyl ofl exacerbations
Improvel lungl functionl andl symptoms
Decreasel hospitalizationsl andl mortality
Improvel qualityl ofl life
Q:l Combinedl Assessmentl ofl COPDl (GOLDl Classification)
Answer:
Thel GOLDl (Globall Initiativel forl Chronicl Obstructivel Lungl Disease)l systeml usesl al
combinedl assessmentl tol guidel treatmentl decisions.l Itl evaluatesl threel keyl components:
Symptoms
Riskl ofl exacerbations
Spirometryl (airflowl limitation)
Thesel factorsl helpl categorizel patientsl intol Groupl A,l B,l orl E,l whichl determinesl thel
appropriatel treatmentl approach.
Q:l GOLDl COPDl Risk/Symptom
Answer:
1.l Symptoml Assessment
CATl (COPDl Assessmentl Test)
Questionnairel measuringl impactl ofl COPDl onl dailyl life.
CATl ≥l 10l →l Morel symptomatic
CATl <l 10l →l Lessl symptomatic
mMRCl (Modifiedl Medicall Researchl Councill Dyspneal Scale)
Measuresl levell ofl breathlessness.
mMRCl 0-1l →l Lessl symptoms
mMRCl ≥l 2l →l Morel symptoms
Thesel scoresl helpl determinel whetherl thel patientl hasl lowl orl highl symptoml burden.
2.l Riskl ofl Exacerbations
Exacerbationl riskl isl basedl onl historyl ofl COPDl exacerbationsl inl thel pastl year.
Lowl Risk
0-1l exacerbation
Nol hospitalizations
Highl Risk
≥2l exacerbations,l OR
≥1l exacerbationl requiringl hospitalization
, Q:l GOLDl Groupl A
Answer:
Groupl A
Lowl symptomsl +l lowl exacerbationl risk
Criteria:
CATl <l 10l orl mMRCl 0-1
0-1l exacerbationl withoutl hospitalization
Recommendedl therapy
Singlel bronchodilator
SABA
SAMA
LABA
LAMA
Ifl symptomsl continue
Reviewl adherencel andl inhalerl technique
Escalatel tol LAMAl +l LABA
Considerl switchingl inhalerl devicel orl medication
Q:l GOLDl Groupl B
Answer:
Morel symptomsl +l lowl exacerbationl risk
Criteria:
CATl ≥l 10l orl mMRCl ≥l 2
0-1l exacerbationl withoutl hospitalization
Recommendedl therapy
LABAl orl LAMA
Ifl symptomsl persistl →l LABAl +l LAMA
Thisl providesl greaterl bronchodilationl andl symptoml reliefl thanl al singlel bronchodilator.
Q:l GOLDl Groupl E
Answer:
Highl exacerbationl risk
Criteria:
Pharmacologyl Guide|l Wilkesl (Latestl
2026/l 2027l Update)l 100%l Verifiedl
Questionsl &l Answersl |l Gradel A
Q:l Vaccinationsl COPD
Answer:
Influenzal vaccine
Pneumococcall vaccine
PCV20l (pneumococcall conjugatel vaccine)l OR
PCV15l followedl byl PPSV23
COVID-19l Vaccine
Pertussisl (Tdap)
Shinglesl (herpesl zoster)
RSV
Thesel reducel riskl ofl respiratoryl infectionsl andl COPDl exacerbations.
Q:l Differencesl inl Pathophysiologyl Betweenl COPDl andl Asthmal andl Theirl Impactl onl
Treatment
Answer:
Pathophysiologyl ofl Asthma
Asthmal isl al chronicl inflammatoryl airwayl diseasel characterizedl by:
Airwayl inflammation
Bronchiall hyperresponsiveness
Reversiblel airflowl obstruction
Thel airwayl narrowingl isl primarilyl duel tol inflammation,l bronchospasm,l andl mucusl
production.
Thel airflowl limitationl inl asthmal isl typicallyl reversiblel withl bronchodilators.
Therapeuticl Approach
Becausel inflammationl isl thel mainl driver,l treatmentl focusesl onl anti-inflammatoryl therapy.
Inhaledl corticosteroidsl (ICS)l arel thel foundationl ofl asthmal treatment.
,Bronchodilatorsl (SABAl orl LABA)l arel usedl tol relievel bronchospasml andl improvel
airflow.
Pathophysiologyl ofl COPD
COPDl isl characterizedl byl chronicl airflowl limitationl thatl isl notl fullyl reversible.
Thel diseasel resultsl from:
Chronicl airwayl inflammation
Structurall airwayl damage
Alveolarl destructionl (emphysema)
Excessl mucusl productionl (chronicl bronchitis)
Thesel changesl cause:
Narrowedl airways
Lossl ofl elasticl recoil
Persistentl airflowl obstruction
Spirometryl isl requiredl forl diagnosis.l COPDl isl confirmedl whenl post-bronchodilatorl
FEV₁/FVCl <l 0.70,l indicatingl persistentl airflowl limitation
Q:l Therapeuticl differencesl inl Asthmal andl COPD
Answer:
Asthma
Focusl onl anti-inflammatoryl therapy
ICSl arel first-linel controllerl medications
COPD
Focusl onl bronchodilationl andl symptoml control
Bronchodilatorsl (LABAl andl LAMA)l arel thel foundationl ofl COPDl therapy
ICSl arel usedl onlyl inl certainl patients,l suchl asl thosel withl frequentl exacerbations
Q:l Majorl Riskl Factorsl COPD
Answer:
1-l Smoking
2-l Age
3-l Male
4-l Impairedl lungl growth
5-l Occupation
6-l Alpha1-l antitrypsinl deficiency
Whyl Providersl Shouldl Encouragel Riskl Factorl Reduction
Reducingl riskl factorsl isl essentiall becausel itl can:
,Slowl diseasel progression
Reducel frequencyl ofl exacerbations
Improvel lungl functionl andl symptoms
Decreasel hospitalizationsl andl mortality
Improvel qualityl ofl life
Q:l Combinedl Assessmentl ofl COPDl (GOLDl Classification)
Answer:
Thel GOLDl (Globall Initiativel forl Chronicl Obstructivel Lungl Disease)l systeml usesl al
combinedl assessmentl tol guidel treatmentl decisions.l Itl evaluatesl threel keyl components:
Symptoms
Riskl ofl exacerbations
Spirometryl (airflowl limitation)
Thesel factorsl helpl categorizel patientsl intol Groupl A,l B,l orl E,l whichl determinesl thel
appropriatel treatmentl approach.
Q:l GOLDl COPDl Risk/Symptom
Answer:
1.l Symptoml Assessment
CATl (COPDl Assessmentl Test)
Questionnairel measuringl impactl ofl COPDl onl dailyl life.
CATl ≥l 10l →l Morel symptomatic
CATl <l 10l →l Lessl symptomatic
mMRCl (Modifiedl Medicall Researchl Councill Dyspneal Scale)
Measuresl levell ofl breathlessness.
mMRCl 0-1l →l Lessl symptoms
mMRCl ≥l 2l →l Morel symptoms
Thesel scoresl helpl determinel whetherl thel patientl hasl lowl orl highl symptoml burden.
2.l Riskl ofl Exacerbations
Exacerbationl riskl isl basedl onl historyl ofl COPDl exacerbationsl inl thel pastl year.
Lowl Risk
0-1l exacerbation
Nol hospitalizations
Highl Risk
≥2l exacerbations,l OR
≥1l exacerbationl requiringl hospitalization
, Q:l GOLDl Groupl A
Answer:
Groupl A
Lowl symptomsl +l lowl exacerbationl risk
Criteria:
CATl <l 10l orl mMRCl 0-1
0-1l exacerbationl withoutl hospitalization
Recommendedl therapy
Singlel bronchodilator
SABA
SAMA
LABA
LAMA
Ifl symptomsl continue
Reviewl adherencel andl inhalerl technique
Escalatel tol LAMAl +l LABA
Considerl switchingl inhalerl devicel orl medication
Q:l GOLDl Groupl B
Answer:
Morel symptomsl +l lowl exacerbationl risk
Criteria:
CATl ≥l 10l orl mMRCl ≥l 2
0-1l exacerbationl withoutl hospitalization
Recommendedl therapy
LABAl orl LAMA
Ifl symptomsl persistl →l LABAl +l LAMA
Thisl providesl greaterl bronchodilationl andl symptoml reliefl thanl al singlel bronchodilator.
Q:l GOLDl Groupl E
Answer:
Highl exacerbationl risk
Criteria:
